What role does Arcera Life Sciences play in building collaborative healthcare ecosystems?
At Arcera, our role is to help connect and activate the healthcare ecosystem so innovation can translate into real outcomes for patients.
Healthcare progress today depends on alignment across many entities. Researchers, regulators, clinicians, technology leaders, and industry must work together to turn scientific progress into solutions that reach people at scale.
This philosophy was visible during our “Catalyst: Collaborating to Turn AI Vision to Value” Forum in Abu Dhabi, where we brought together policymakers, clinicians, academics, and technology leaders to focus on a shared goal: how to turn healthcare ambition into measurable system impact.
We are working across this landscape, partnering with governments, academia, and industry to translate scientific innovation into real and timely access for patients.
Anchored in Abu Dhabi, we benefit from the UAE’s forward-looking regulatory environment and strong digital infrastructure, which allow us to implement and scale new healthcare models regionally and globally. This approach helps address complex challenges such as chronic diseases, antimicrobial resistance, and population ageing in a coordinated way.
Our objective is to facilitate effective collaboration, enabling innovation to reach patients more rapidly, sustainably, and on a larger scale.
What needs to happen next for AI to become truly embedded in healthcare delivery?
AI is transforming healthcare as it moves from experimentation to integration.
The technology itself is not the barrier to speed and impact. The real challenge is embedding AI into clinical workflows, decision-making processes, and governance frameworks in ways that build trust and deliver measurable value.
AI solutions must start with real clinical and system needs rather than abstract use cases. That means clinicians, health system leaders, and technology developers must work together from the outset to design tools that augment decision-making rather than add complexity.
Trust is equally essential. AI must be transparent, explainable, and supported by strong regulatory and ethical oversight, so clinicians and patients understand how decisions are made.
Finally, leadership matters. Healthcare organizations must treat AI as a strategic capability, not simply an IT project. That means investing in talent, governance, and accountability structures that allow AI to improve clinical, operational, and financial decision-making.
When AI becomes embedded in how healthcare systems operate, it can move from isolated improvements to true system transformation.
What role do public-private-academic partnerships play in accelerating outcomes?
Healthcare challenges today are too complex for any single institution to solve alone.
Public-private-academic partnerships allow different strengths to come together. Academic institutions provide scientific rigor and evidence generation. Governments create the policy frameworks and long-term system perspective needed for sustainable change. The private sector brings agility, investment, and the ability to translate innovation into deployable solutions.
At Arcera, we view these collaborations as long-term capability building, not one-off initiatives.
Our partnership with the ISPOR UAE Chapter is a good example. By working together to advance health economics and outcomes research and strengthen health technology assessment capability, we are helping ensure that innovations are evaluated and integrated into healthcare systems in a sustainable way.
These partnerships ultimately ensure that innovation is not an isolated breakthrough but part of a continuous cycle of healthcare evolution.
What lessons from other industries should healthcare adopt when scaling AI?
One of the most important lessons from other industries is that technology scales only when organizations are ready for it.
In sectors like finance, aviation, and advanced manufacturing, AI succeeded because companies embedded it into core operations and decision-making rather than treating it as an innovation project.
Healthcare must follow the same path. Scaling AI requires clear leadership ownership, defined performance metrics, and continuous monitoring of outcomes.
Trust is also essential. Industries that adopted AI successfully invested early in transparency, explainability, and strong risk management frameworks so users understood the systems they relied on.
Another key factor is talent. Healthcare organizations must invest in training and upskilling so professionals can work confidently alongside AI tools.
Ultimately, the lesson is simple: AI succeeds when it becomes part of how organizations think, decide, and operate.
How is AI going to change the way Arcera operates in the next few years?
At Arcera, we see AI as a capability that will strengthen how we make decisions and deliver value.
AI is increasingly supporting how we assess opportunities, allocate resources, and monitor outcomes across our global operations. It will ultimately allow us to interpret complex data more effectively, manage risk more proactively, and respond faster to evolving healthcare needs.
It will also enhance collaboration with our partners by enabling stronger data sharing and supporting better outcomes.
However, our approach is disciplined. We do not deploy AI for its own sake. We integrate it where it can bring the best impact on improving decision quality, operational efficiency, and patient outcomes.
Governance will remain a priority. Responsible adoption requires strong ethical frameworks, regulatory alignment, and clear oversight.
When used thoughtfully, AI becomes a powerful enabler of our mission to help people live longer and healthier lives.
What are your plans for the coming years?
Our focus is to continue strengthening Arcera as a global life sciences platform anchored in Abu Dhabi.
We are pursuing a disciplined strategy that combines organic growth with targeted acquisitions, particularly expanding our geographic footprint and focusing on therapeutic areas with significant unmet need such as cardiometabolic diseases, neuroscience, oncology, and rare diseases.
Innovation remains central to our strategy. Beyond advancing therapies, we are investing in digital capabilities, AI-enabled decision-making, and data-driven tools that improve outcomes and support healthcare system sustainability.
At the same time, we are committed to supporting the UAE’s ambition to become a global life sciences hub. By investing in partnerships, talent development, and advanced manufacturing capabilities, we aim to contribute to a healthcare ecosystem that drives regional and global impact.
Our ambition is clear: to translate innovation into real patient impact while strengthening resilient healthcare systems across the markets we serve globally.
